# PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma

> **NCT06125223** · — · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck
- Neoadjuvant Therapy
- Immunotherapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06125223
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125223, "PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06125223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*